Recently, IntelliCyt introduced a new high-content screening platform, based on flow cytometry detection, called the iQue™ Screener.
Developed to complement high-content imaging, the iQue Screener is optimized for suspension assay formats with cells, beads, microbes, and mixtures. The platform provides a mechanism for subpopulation phenotyping—where multiple subpopulations are identified by size and density then correlated with intensities of multiple fluorescent probes on a per object basis.
Researchers can rapidly profile compound effects on nonadherent cell lines, including primary immune system cells, and determine molecular interactions using cell or bead-based assays.
The iQue Screener platform operates with ForeCyt® Data Acquisition and Analysis Software featuring low-volume, high-throughput, multiplexed endpoints in an automation-friendly system. Screening is carried out in terms of relevant metrics (hits or dose responses, which can be identified directly from the software), and multiplexed datasets are easily correlated for relevance.
So IntelliCyt can help to generate the right data, but what about providing information at the right point in the process? It is generally agreed that the earlier that information on the compound activity profile can be obtained, the better the decisions will be. Positioning an assay earlier in the drug discovery process requires higher capacity, reasonable cost, and the confidence that comes from scalable, reproducible, and statistically relevant sampling.